DeCure for Ovarian clear cell malignant adenofibroma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for ovarian clear cell malignant adenofibroma — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian clear cell malignant adenofibroma maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian clear cell malignant adenofibroma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tumor protein p53 (TP53) — TP53 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9R2Q · 3.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In a 1999 study of 51 epithelial ovarian carcinomas, clear cell carcinoma showed low expression of p53 and cyclin A and significantly increased expression of p21 and cyclin E compared with other histologic subtypes. A strong positive correlation was found between p53 and cyclin A staining across all carcinomas, and a weaker correlation between p21 and cyclin E. Clinical stage was the only independent predictor of survival; histologic subtype did not correlate with survival in that analysis.
A 2010 case report describes a borderline clear cell adenofibroma in a 52-year-old postmenopausal woman. The tumour had central extensive haemorrhagic necrosis, which made invasiveness impossible to assess. The report states that the prognosis of borderline clear cell adenofibroma is excellent, but long-term follow-up was needed for that patient.
A 2016 case describes a patient who had fertility-sparing surgery for Stage IA clear cell carcinoma at age 33 and developed a tumour in the contralateral ovary nine years later. That tumour was pathologically diagnosed as clear cell carcinoma with clear cell adenofibroma, possibly de novo. The authors note a consensus that fertility-sparing surgery is an option for Stage IA clear cell carcinoma, but long-term monitoring is advised for recurrence or de novo contralateral disease.
A 2019 case report states that clear cell carcinoma of the ovary is rare in pregnancy and is attributed to development from endometriosis. It describes the tumour as aggressive with a worse prognosis and low survival rate due to chemo resistance. The report says treatment options for advanced stages are still under research. What is missing for this disease are prospective trials large enough to account for its rarity, validated biomarkers to stratify patients by risk of recurrence or contralateral development, and effective systemic therapies for advanced or chemo-resistant disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 1999 · 92 citations
Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas
AbstractBACKGROUND: The purpose of this study was to identify biologic differences between ovarian clear cell carcinoma and other ovarian adenocarcinomas by comparing the expression of cell cycle regulatory molecules and by analyzing the survival of the patients. METHODS: In 51 cases of epithelial ovarian carcinoma, the expression of the cell proliferation marker Ki-67 and that of the cell cycle regulatory molecules p53, p16, p21, p27, cyclin E, and cyclin A was studied using immunohistochemical techniques. The correlations among clinical stage, histologic subtype, labeling index for Ki-67, and expression of these cell cycle regulators were examined statistically. Multivariate survival analysis was performed using these factors in the Cox proportional hazards model. RESULTS: Clear cell carcinoma revealed such trends as low expression of both p53 and cyclin A and significantly increased expression of both p21 and cyclin E (compared with the other histologic subtypes). In all ovarian carcinomas, a very strong positive correlation (correlation coefficient 0.79; P < 0.0001) between p53 positive staining and cyclin A positive staining and a weak positive correlation (correlation coefficient 0.47; P < 0.01) between p21 positive staining and cyclin E positive staining were recognized at the level of expression of cell cycle regulatory molecules. Clinical stage was the only independent predictive factor for the survival of the patients. CONCLUSIONS: Among ovarian adenocarcinomas, clear cell carcinoma exhibits a unique pattern of expression of cell cycle regulatory molecules, though in this study the survival of the patients did not correlate with histologic subtype, only with clinical stage.
Hematology/Oncology and Stem Cell Therapy · 2010 · 7 citations · open access
Borderline clear cell adenofibroma with extensive hemorrhagic necrosis
AbstractBorderline clear cell adenofibroma of the ovary is rather rare since most of clear cell tumors are carcinomas. We report a case of ovarian borderline clear cell adenofibroma in a 52-year-old postmenopausal woman. The tumor had the characteristic histologic features of borderline clear cell adenofibroma except for central extensive hemorrhagic necrosis. The prognosis of borderline clear cell adenofibroma is excellent. Because the invasiveness cannot be assessed in the necrotic areas, our patient needed long-term follow-up.
International Cancer Conference Journal · 2016 · 2 citations · open access
Possible de novo clear cell carcinoma in the contralateral ovary 9 years after fertility-sparing surgery for Stage IA clear cell ovarian carcinoma
AbstractA patient who underwent fertility-sparing surgery for Stage IA clear cell carcinoma may have developed de novo clear cell carcinoma in the contralateral ovary 9 years later. She underwent fertility-sparing surgery and postoperative adjuvant chemotherapy for right ovarian carcinoma at 33 years of age (when endometriosis was observed in the contralateral ovary). At the age of 41 years, a tumor was discovered in the left ovary. This was diagnosed pathologically as clear cell carcinoma with clear cell adenofibroma, which may have developed de novo. A consensus is currently taking shape that although fertility-sparing surgery is a therapeutic option for patients with Stage IA clear cell carcinoma, long-term outpatient monitoring is advised to watch for its recurrence or de novo development in the contralateral ovary.
International Journal of Reproduction Contraception Obstetrics and Gynecology · 2019 · 0 citations · open access
A rare case of endometriosis to clear cell ovarian carcinoma: a case report
AbstractClear cell carcinoma of ovary is a rare tumour with a very low incidence in pregnancy. It is attributed to develop from an existing background of endometriosis. There are very few case reports of the above combination tumours in pregnancy. It is a very aggressive tumour with a worse prognosis and low survival rate because of its peculiar chemo resistant nature. Early detection and effective treatment are the best approach. The treatment options for advanced stages are still under research.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
